AMYVID Drug Patent Profile
✉ Email this page to a colleague
When do Amyvid patents expire, and what generic alternatives are available?
Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries.
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Amyvid
Amyvid was eligible for patent challenges on April 6, 2016.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 30, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMYVID?
- What are the global sales for AMYVID?
- What is Average Wholesale Price for AMYVID?
Summary for AMYVID
| International Patents: | 51 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Clinical Trials: | 39 |
| Patent Applications: | 160 |
| What excipients (inactive ingredients) are in AMYVID? | AMYVID excipients list |
| DailyMed Link: | AMYVID at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AMYVID
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for AMYVID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Puerto Rico | Phase 2 |
| Universidad Central del Caribe | Phase 2 |
| Invicro | Phase 1 |
Pharmacology for AMYVID
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for AMYVID
AMYVID is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AMYVID is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting AMYVID
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-003 | Apr 6, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-002 | Apr 6, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-004 | Oct 13, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AMYVID
When does loss-of-exclusivity occur for AMYVID?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07243712
Patent: Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
Austria
Patent: 39060
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0710225
Patent: derivados de estirilpiridina e sua utilização para ligar e visualizar placas amilóides
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 44530
Patent: DERIVES DE STYRYLPYRIDINE ET LEURS APPLICATIONS A LA LIAISONET A L'IMAGERIE DE PLAQUES AMYLOIDES (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1522624
Patent: Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 329
Patent: DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNION A PLACAS AMILOIDES Y OBTENCION DE IMAGENES DE LAS MISMAS
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0120135
Estimated Expiration: ⤷ Sign Up
Patent: 0170857
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 13048
Estimated Expiration: ⤷ Sign Up
Patent: 19048
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 99109
Estimated Expiration: ⤷ Sign Up
Patent: 63392
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 088783
Patent: DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNIÓN A PLACAS AMILOIDES Y OBTENCIÓN DE IMÁGENES DE LAS MISMAS
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 7898
Patent: СТИРИЛПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Patent: 0870389
Patent: СТИРИЛПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 99109
Patent: DÉRIVÉS DE STYRYLPYRIDINE ET LEURS APPLICATIONS À LA LIAISON ET À L'IMAGERIE DE PLAQUES AMYLOÏDES (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Patent: 63391
Patent: Dérivés de stilbène et leur utilisation pour la liaison et l'imagerie de plaques amyloïdes (Styrylpyridine derivatives and their use for binding and imaging amyloid plaques)
Estimated Expiration: ⤷ Sign Up
Patent: 63392
Patent: DÉRIVÉS DE STILBÈNE ET LEUR UTILISATION POUR LA LIAISON ET L'IMAGERIE DE PLAQUES AMYLOÏDES (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
France
Patent: C0034
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 0800201
Patent: DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNION A PLACAS AMILOIDES Y OBTENCIÓN DE IMAGENES DE LAS MISMAS.
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 32660
Estimated Expiration: ⤷ Sign Up
Patent: 300028
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3567
Patent: סטרילפירידין ותולדות סטרילפירידין מסומנות רדיואקטיבית, תכשירים המכילים אותם, תכשירים דיאגנוסטיים והשימוש בהם (Styrylpyridine and radiolabeled styrylpyridine derivatives, compositions comprising them, diagnostic compositions and uses thereof)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 90954
Estimated Expiration: ⤷ Sign Up
Patent: 09532349
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 63392
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 232
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 08012527
Patent: DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNION A PLACAS AMILOIDES Y OBTENCION DE IMAGENES DE LAS MISMAS. (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0887
Patent: Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 2090
Estimated Expiration: ⤷ Sign Up
Patent: 18030
Estimated Expiration: ⤷ Sign Up
Patent: 084590
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 99109
Estimated Expiration: ⤷ Sign Up
Patent: 63392
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 99109
Estimated Expiration: ⤷ Sign Up
Patent: 63392
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 222
Patent: DERIVATI STIRILPIRIDINA I NJIHOVA UPOTREBA ZA VEZIVANJE I IMIDŽING AMILOIDNIH PLAKOVA (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Patent: 171
Patent: DERIVATI STIRILPIRIDINA I NJIHOVA UPOTREBA ZA VEZIVANJE I IMIDŽING AMILOIDNIH PLAKOVA (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 3338
Patent: STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 99109
Estimated Expiration: ⤷ Sign Up
Patent: 63392
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0807955
Patent: STRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1376807
Estimated Expiration: ⤷ Sign Up
Patent: 080106564
Patent: STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 78785
Estimated Expiration: ⤷ Sign Up
Patent: 28882
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 99366
Estimated Expiration: ⤷ Sign Up
Patent: 0838852
Patent: Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 802
Patent: СТИРИЛПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК;СТИРИЛПІРИДИНОВІ ПОХІДНІ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ЗВ'ЯЗУВАННЯ І ВІЗУАЛІЗАЦІЇ АМІЛОЇДНИХ БЛЯШОК (STYRYLPYRIDINE COMPOUNDS USEFUL AND USE THEREOF IN IMAGING AMYLOID DEPOSITS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering AMYVID around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 1113048 | ⤷ Sign Up | |
| Poland | 2363392 | ⤷ Sign Up | |
| Luxembourg | 92232 | ⤷ Sign Up | |
| Portugal | 1999109 | ⤷ Sign Up | |
| Croatia | P20170857 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AMYVID
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1999109 | C01999109/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: SWISSMEDIC 62897 09.01.2014 |
| 1999109 | 92232 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: FLORBETAPIR (18 F) |
| 1999109 | C 2013 023 | Romania | ⤷ Sign Up | PRODUCT NAME: FLORBETAPIR(18F)4-[(1E)-2-(6-{2-[2-(2-[18F]FLUOROETOXI)ETOXI]ETOXI}PIRIDIN-3-IL)ETENIL]-N-METILBENZENAMINA; NATIONAL AUTHORISATION NUMBER: EU/1/12/805; DATE OF NATIONAL AUTHORISATION: 20130114; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/805; DATE OF FIRST AUTHORISATION IN EEA: 20130114 |
| 1999109 | 481 | Finland | ⤷ Sign Up | |
| 1999109 | 2013/028 | Ireland | ⤷ Sign Up | PRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
